Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.

In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from July.

In this installment of our VC Playbook series, In Vivo sits down with Isabelle de Cremoux, CEO of Seventure. The company has been a pioneer investor in the microbiome space, which Cremoux believes has now reached a turning point.

The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.